Attending TCT in Boston in a few weeks? Want to get "wicked smart" about treating coronary calcium? Shockwave has a lot in store for you:
Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Attending TCT in Boston in a few weeks? Want to get "wicked smart" about treating coronary calcium? Shockwave has a lot in store for you:
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
At AMP 2022, Dr. Peter Soukas presented the largest set of real-world data on Shockwave IVL in CLI patients. These data include results from patient groups historically not included in other PAD studies, such as Rutherford 6 and dialysis patients, and patients with single or absent vessel run-off. These data show the significant reduction of stenosis post-IVL in these patients, the minimal complications and the consistent results across multiple vessel beds. In this presentation Dr. Soukas shares why these data are important for physicians who treat CLI, and how his calcium modification algorithm has changed over time with IVL.
Topics: Peripheral IVL, Peripheral Conferences, Peripheral Clinical Data, Shockwave M5 & Shockwave M5+
Dr. Suzanne J. Baron of Lahey Hospital and Medical Center, Burlington, Massachusetts talks about gender disparities of PCI outcomes in calcified lesions, citing the recent SCAI Expert Consensus Statement, which brings to light the under-representation of women in cardiovascular clinical trials. Dr. Baron also talks about the impact of IVL to improve outcomes in women with calcified disease based on the recently published sex specific analysis of Disrupt CAD Pooled data at SCAI 2022.
For more information on Coronary IVL CAD Pooled Gender Analysis data, please visit ItsTimeForAnIntervention.com
Topics: Coronary IVL, Shockwave C2, Calcium Corner
Calcified lesions in CLTI patients pose a number of hurdles for endovascular therapy including acute and sub-acute recoil, flow-limiting dissections and distal embolization. In this presentation from Charing Cross 2022 Dr. Thulasidasan shares how Shockwave IVL has improved his treatment for CLTI patients with low complications and increased durability. Dr. Thulasidasan walks through case examples with IVL in CLTI patients and states how the data supporting IVL backs up what he’s seeing in practice.
Topics: Peripheral IVL, Peripheral Conferences, Peripheral Clinical Data
Dr. Stephan Heo of the New England Heart and Vascular Institute, Catholic Medical Center, Manchester, New Hampshire shares his decision-making process in approaching calcified lesions in complex PCI as well as strategies to deliver IVL with different GEC techniques when facing challenging vessel anatomy and calcium morphology.
Topics: Coronary IVL, Shockwave C2, Calcium Corner
Recognizing Shockwave’s commitment to drive value through clinical excellence and commitment to lower costs, Shockwave was announced a winner of the Supplier Horizon Award from Premier Inc., a leading healthcare improvement and technology company that unites an alliance of more than 4,400 U.S. hospitals and health systems and approximately 225,000 other providers. We're thrilled to be honored by Premier Inc. as a Supplier Horizon winner at the Breakthroughs Conference 2022 as it represents the support provided to Premier members of “exceptional customer service and engagement.”
Shockwave received this award for being a preferred supplier in the healthcare industry and demonstrating “unwavering commitment to delivering top value products and services designed to continually improve patient care.” This award, “recognizes suppliers - with less than three years of Premier tenure in a specific service line - that consistently support our members at the highest levels of partnership, customer service, value creation, clinical excellence, and commitment to lower costs.” Shockwave supports Premier members by offering valuable products and services that help to lower supply chain costs and improve operating efficiencies,” said David A. Hargraves, Senior Vice President, Supply Chain, Premier, “We’re honored to recognize them as a Horizon Award recipient.”
The full list of Premier’s 2022 Supplier Horizon Award winners can be found here.
Topics: IVL Technology, SWAV News
We had an amazing time seeing you all in person at conferences this past quarter. We accomplished a great deal these past three months—from sharing the randomized Disrupt PAD III Study results at SCAI 2022 to launching Shockwave M5+ across the globe. JSCAI also published two articles discussing peripheral IVL for treatment of calcified common femoral artery disease, and the mid-term outcomes from the randomized Disrupt PAD III Trial. Check out the latest in the PulsePoint newsletter!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, PulsePoint Newsletter
At Shockwave, we are committed to doing everything we can to narrow the PCI gender inequality gap starting with clinical evidence presented at SCAI 2022 where Coronary IVL demonstrated sustained long term clinical outcomes and excellent safety in both women and men suggesting first line use of Coronary IVL for plaque modification in female patients with calcified lesions.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Female vs. Male Outcomes
In this three-episode tutorial series, Dr Stefano Fazzini and Dr Michel Bosiers provide an excellent overview on how IVL removes the barriers of calcified hostile access and expands treatment boundaries in EVAR and TEVAR procedures by changing vessel compliance, facilitating luminal gain and significantly reducing complications.
Topics: Peripheral IVL, Peripheral Clinical Data
Leading female interventionalists came together at SCAI 2022 to discuss what they are most excited about in the interventional space today, share key takeaways from SCAI, and discuss the female focused initiatives that will help bridge the PCI gap in gender disparities going forward. From the JSCAI expert consensus, gender focused clinical evidence highlights at SCAI, and future research to SCAI WIN initiatives, these female leaders covered it all.
Listen to the podcast with Dr. Dawn Abbott, MD, Rhode Island Hospital, Dr. Suzanne Baron, MD, Lahey Hospital and Medical Center, Dr. Alexandra Lansky, MD, Yale University School of Medicine, Yale University and Dr. Nadia Sutton, MD, University of Michigan.
We hope you enjoy the episode and for more information on coronary IVL in women, please visit TimeForAnIntervention.com.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Coronary Conferences, ChalkTalk Podcast, Female vs. Male Outcomes